Chronic exposure to environmental contaminant nonylphenol exacerbates adenine-induced chronic renal insufficiency: role of signaling pathways and therapeutic impact of rosuvastatin

Eur J Pharm Sci. 2012 Aug 15;46(5):455-67. doi: 10.1016/j.ejps.2012.03.009. Epub 2012 Mar 29.

Abstract

Although chronic exposure to environmental contaminants is hazardous to health, the association between chronic kidney disease (CKD) and nonylphenol (NP), a common environmental compound, remains unclear. This study tested the hypothesis that chronic NP exposure aggravated adenine (AD)-induced CKD that could be mitigated with rosuvastatin treatment. Fifty Wistar rats were randomly (n=10/each group) categorized into normal controls (N(C)), NP only (2.0mg/kg/day), AD only (0.25% AD in fodder), combined NP-AD, and NP-AD with rosuvastatin (20.0mg/kg/day) (NP-AD-R(OSU)). All animals received treatment for 24 weeks prior to being sacrificed. Results showed that ratio of urine protein to creatinine were increased in NP-AD group than in groups N(C), NP, and AD, but reduced in NP-AD-R(OSU) group compared with NP-AD group (all p<0.003). Protein expression of TGF-β and phosphorylated Smad3, indexes of tissue fibrosis, were increased in NP-AD group than in groups N(C), NP and AD, but reduced in NP-AD-R(OSU) group compared with NP-AD group (all p<0.001). BMP-2 and phosphorylated Smad1/5, two indicators of anti-fibrosis, were lower in NP-AD group than in groups N(C), NP and AD, but higher in NP-AD-R(OSU) group compared with NP-AD group (all p<0.001). Protein expressions of JNK and PKC-α in membranous compartment were higher in group NP-AD than in groups N(C), NP and AD, but reduced in NP-AD-R(OSU) group compared with NP-AD group (all p<0.001). More TGF-β+cells but less BMP-2+, CD31+, vWF+and GR+cells were noted in groups AD and NP-AD than in groups N(C), NP and NP-AD-R(OSU) (all p<0.04). In conclusion, NP exposure worsened aggravated AD-induced CKD that could be ameliorated with rosuvastatin treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine
  • Animals
  • Biomarkers / blood
  • Blood Urea Nitrogen
  • Body Weight / drug effects
  • Creatinine / blood
  • Cytoprotection
  • Disease Models, Animal
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Environmental Pollutants / toxicity*
  • Fibrosis
  • Fluorobenzenes / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Kidney / blood supply
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Male
  • Membrane Glycoproteins / metabolism
  • Mitogen-Activated Protein Kinases / metabolism
  • NADH, NADPH Oxidoreductases / metabolism
  • NADPH Oxidase 1
  • NADPH Oxidase 2
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects
  • Phenols / toxicity*
  • Protein Kinase C / metabolism
  • Proteinuria / chemically induced
  • Proteinuria / drug therapy
  • Proteinuria / metabolism
  • Pyrimidines / pharmacology*
  • Rats
  • Rats, Wistar
  • Renal Insufficiency, Chronic / chemically induced*
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / metabolism
  • Renal Insufficiency, Chronic / pathology
  • Rosuvastatin Calcium
  • Signal Transduction / drug effects*
  • Sulfonamides / pharmacology*
  • Time Factors

Substances

  • Biomarkers
  • Environmental Pollutants
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Membrane Glycoproteins
  • Phenols
  • Pyrimidines
  • Sulfonamides
  • nonylphenol
  • Rosuvastatin Calcium
  • Creatinine
  • NADH, NADPH Oxidoreductases
  • Cybb protein, rat
  • NADPH Oxidase 1
  • NADPH Oxidase 2
  • NADPH Oxidases
  • Protein Kinase C
  • Mitogen-Activated Protein Kinases
  • Adenine